Teriparatide
approvedAlso known as: Forteo, PTH(1-34)
**Mechanism of Action** Teriparatide (recombinant human parathyroid hormone [1-34]) exerts its effects through intermittent activation of the PTH1 receptor on osteoblasts. Unlike continuous PTH exposure, which promotes bone resorption, daily subcutaneous administration of teriparatide preferentially stimulates osteoblast activity, increasing bone formation markers (e.g., P1NP, osteocalcin) and enhancing trabecular connectivity and cortical thickness. This anabolic action is mediated via upregulation of Wnt/β-catenin signaling, IGF-1, and Runx2 transcription factors, leading to improved bone mineral density (BMD) and microarchitecture. **Key Research Findings** Over 2,964 PubMed-indexed studies support teriparatide’s efficacy. The pivotal Fracture Prevention Trial (Neer et al., 2001) demonstrated a 65% reduction in vertebral fractures and 53% reduction in nonvertebral fractures in postmenopausal women with severe osteoporosis. Subsequent research confirmed its superiority over antiresorptives in increasing lumbar spine BMD (9–13% over 18–24 months) and reducing fracture risk in glucocorticoid-induced osteoporosis and hypogonadal men. Duration of therapy is limited to 24 months due to theoretical osteosarcoma risk observed in rat models, though human data show no confirmed causal link. **Clinical Relevance** Teriparatide is FDA-approved for postmenopausal women and men with severe osteoporosis (T-score ≤ -3.5 or fragility fractures), glucocorticoid-induced osteoporosis, and hypogonadal osteoporosis. It is reserved for patients at high fracture risk or those who fail/intolerant to bisphosphonates. Sequential therapy with antiresorptives (e.g., denosumab) is recommended post-treatment to maintain gains. Monitoring includes serum calcium and renal function due to transient hypercalcemia risk. For research purposes only — not medical advice.
Key data
C181H291N55O51S2Research & studies
Abaloparatide showed advantage over teriparatide for non-vertebral fractures (OR: 0.87, 95% CI: 0.80-0.95) and hip fractures (OR: 0.81, 95% CI: 0.71-0.93).; Teriparatide and abaloparatide were superior to placebo, raloxifene, and calcitonin in reducing vertebral fractures; teriparatide was also superior to denosumab and risedronate.; For non-vertebral fractures, abaloparatide was better than any other treatment, while teriparatide was only superior to alendronate or placebo.; Both agents had comparable safety to other osteoporosis treatments, with no increased cardiovascular risk.
Hip fracture incidence was lower with abaloparatide (1.1%) vs teriparatide (1.4%) over 18 months (HR 0.83, p=0.027).; Nonvertebral fracture incidence was lower with abaloparatide (4.4%) vs teriparatide (5.0%) (HR 0.88, p=0.003).; No significant treatment-subgroup interactions were observed for age, prior antiresorptive use, or prior fracture.; Cardiovascular event rates were similar between the two treatment groups.
Teriparatide and abaloparatide are PTH-related analogues; romosozumab is an anti-sclerostin agent approved only for female patients.; Efficacy in preventing fragility fractures is widely demonstrated.; Serious side effects, including malignancy risk with teriparatide and cardiovascular events with romosozumab, have been progressively downgraded.; Further data are needed on their efficacy in glucocorticoid-induced osteoporosis and fracture healing.
Weighted incidence rate difference for nonvertebral fracture was -0.08 per 100 person-years (HR 0.95, 95% CI 0.81-1.12).; Weighted incidence rate difference for hip fracture was 0.00 per 100 person-years (HR 0.99, 95% CI 0.76-1.29).; Weighted incidence rate difference for major adverse cardiac events was -0.06 per 100 person-years (HR 0.90, 95% CI 0.68-1.19).; Romosozumab and teriparatide showed comparable fracture prevention and cardiovascular safety over 365 days of follow-up.
Lumbar spine BMD increased by +10.8% in the T2R group (p<.001) versus -0.0% in the R2T group (p=.875).; Total hip and femoral neck BMD changes were +4.4% and +4.4% in T2R, but -1.3% and -0.8% in R2T.; BMD changes at all sites were significantly higher in T2R compared to R2T (p<.001).; Only the T2R group showed a significant increase in the proportion of patients achieving a lumbar spine T-score above -2.5.
Teriparatide significantly decreased fracture risk versus bisphosphonates (RR 0.61, 95% CI 0.51-0.74).; Denosumab showed no fracture risk reduction versus bisphosphonates (RR 0.99, 95% CI 0.62-1.57).; Both teriparatide and denosumab significantly improved femoral neck, total hip, and lumbar spine BMD versus bisphosphonates.; Neither teriparatide nor denosumab increased adverse event incidence compared to bisphosphonates.
Romosozumab for 3–12 months increased mean HU from 85 to 107 (26% increase, p=0.012).; Teriparatide for >12 months increased mean HU from 106 to 132 (25% increase, p=0.039).; No significant HU change with teriparatide for 3–12 months, denosumab >12 months, or alendronate >12 months.; Romosozumab may be preferred for preoperative optimization due to shorter effective treatment duration.
Frequently asked questions
What is Teriparatide?
**Mechanism of Action** Teriparatide (recombinant human parathyroid hormone [1-34]) exerts its effects through intermittent activation of the PTH1 receptor on osteoblasts. Unlike continuous PTH exposure, which promotes bone resorption, daily subcutaneous administration of teriparatide preferentially stimulates osteobla
How does Teriparatide work?
Recombinant PTH(1-34) that, given intermittently, stimulates osteoblastic bone formation; approved for severe osteoporosis.
What is the research status of Teriparatide?
Teriparatide is currently classified as approved, with 3,006 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of Teriparatide?
Teriparatide has a molecular weight of approximately 4118 g/mol (formula C181H291N55O51S2).
Related peptides
Long-acting somatostatin analog that inhibits GH, glucagon, and gut hormone secretion; used for acromegaly and neuroendocrine tumors.
Depot somatostatin analog inhibiting GH/IGF-1 and neuroendocrine secretion; approved for acromegaly and GEP-NETs.
36-aa HIV gp41 fusion inhibitor that blocks viral entry into CD4 cells; first-in-class antiretroviral fusion inhibitor.
Selective bradykinin B2 receptor antagonist decapeptide approved for acute attacks of hereditary angioedema.
PTHrP(1-34) analog that selectively favors bone anabolism with less hypercalcemia than teriparatide; approved for osteoporosis.
Build on Teriparatide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key